Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator
- PMID: 9843178
Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator
Abstract
The low density lipoprotein receptor-related protein (LRP), a multi-functional endocytic receptor, mediates the cellular internalization of tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activator and their complexes with plasminogen activator inhibitor type 1 (PAI-1). LRP preferentially binds the complexed forms, exemplified by equilibrium dissociation constants (KD) that are at least an order of magnitude lower than those of the free components. To understand the molecular interactions, underlying the preference of the receptor for complexes rather than for the free components, we have performed a detailed analysis of the affinity and kinetics of the binding of PAI-1 and t-PA:PAI-1 complexes to the receptor, using surface plasmon resonance. To assess the involvement of the heparin-binding domain of PAI-1 for the interaction with LRP, we determined the equilibrium dissociation constants for the binding to LRP of a panel of PAI-1 mutants with single- and multiple amino-acid substitutions of the basic residues that constitute the heparin binding site of PAI-1 (K65, K69, R76, K80 and K88). The binding of these PAI-1 mutants was partially reduced with a 2 to 4 fold increase in KD values for single (K80, K88) and combined (K80, 88) substitution mutant proteins respectively. LRP binding of complexes, composed of t-PA with either wild type PAI-1 or any one of the single PAI-1 mutants indicated a major role of lysine 69 (K69) for the binding of t-PA:PAI-1 complexes to LRP (KD values of 6.1, 3.7. 75.4, 5.4, 12.5 and 8.1 nM for wild type, K65A, K69A, R76A, K80A and K88A complexes, respectively). Since the KD for the binding of free t-PA to LRP is 158 nM, we conclude that the PAI-1 moiety harbors the major determinant for t-PA:PAI-1 complex binding to LRP. The in vitro binding studies were extended by binding and clearance studies with COS-1 cells. Degradation of both 125I-t-PA:PAI-1 K69A and 125I-t-PA:PAI-1 K69A K80A K88A complexes after 2 h of incubation was reduced compared to the degradation of 125I-t-PA:PAI-1 complexes. We conclude that PAI-1 contains a cryptic binding site (lysine 69) for LRP, that is specifically expressed upon t-PA:PAI-1 complex formation.
Similar articles
-
Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?Thromb Haemost. 2000 Feb;83(2):290-6. Thromb Haemost. 2000. PMID: 10739388
-
Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.FEBS J. 2006 Nov;273(22):5143-59. doi: 10.1111/j.1742-4658.2006.05511.x. Epub 2006 Oct 17. FEBS J. 2006. PMID: 17042782
-
Pregnancy zone protein-tissue-type plasminogen activator complexes bind to low-density lipoprotein receptor-related protein (LRP).Arch Biochem Biophys. 2001 May 15;389(2):218-22. doi: 10.1006/abbi.2001.2329. Arch Biochem Biophys. 2001. PMID: 11339811
-
Clearance receptors for tissue-type plasminogen activator.Int J Hematol. 1994 Aug;60(2):97-109. Int J Hematol. 1994. PMID: 7948967 Review.
-
Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.Semin Thromb Hemost. 2008 Sep;34(6):562-8. doi: 10.1055/s-0028-1103367. Epub 2008 Nov 28. Semin Thromb Hemost. 2008. PMID: 19085655 Review.
Cited by
-
Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.J Biol Chem. 2009 Jul 3;284(27):17989-97. doi: 10.1074/jbc.M109.009530. Epub 2009 May 13. J Biol Chem. 2009. PMID: 19439404 Free PMC article.
-
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.Mol Med Ther. 2012 Aug 5;1(1):101. doi: 10.4172/2324-8769.1000102. Mol Med Ther. 2012. PMID: 23936868 Free PMC article.
-
Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.Biochem J. 2016 Aug 1;473(15):2273-93. doi: 10.1042/BCJ20160014. Biochem J. 2016. PMID: 27470592 Free PMC article. Review.
-
Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.Biochem J. 2001 Jul 1;357(Pt 1):289-96. doi: 10.1042/0264-6021:3570289. Biochem J. 2001. PMID: 11415462 Free PMC article.
-
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 33415130 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous